Abstract：
BACKGROUND: Celiac disease (CeD) is an immune-mediated disorder affecting the small bowel, associated with genetic factors and increasing global prevalence.
OBJECTIVE: This study explores the association between CeD, Systemic Lupus Erythematosus (SLE), primary Sjogren syndrome (pSS), and Systemic Sclerosis (SSc).
METHODS: A systematic review and meta-analysis were conducted following PRISMA guidelines. Searches across multiple databases yielded 2728 articles, with 15 studies selected. Data extraction included study characteristics, prevalence of CeD and CeD antibodies in SLE, pSS, and SSc. Quality assessment utilized the Newcastle-Ottawa Scale.
RESULTS: The meta-analysis revealed a pooled prevalence of biopsy-proven CeD in SLE, pSS, and SSc of approximately 3%. Seroprevalence of any CeD antibody in SLE, pSS, and SSc ranged from 3% to 10%. Notably, pSS exhibited the highest prevalence at 5.59%. High heterogeneity was observed in seroprevalence across autoimmune conditions. Quality assessment indicated robust methodological quality in the selected studies.
CONCLUSIONS: This study highlights a significantly higher prevalence of CeD, especially pSS, compared to the general population. The findings underscore the importance of recognizing elevated CeD antibodies in patients with SLE, pSS and SSc emphasizing the need for early detection and comprehensive care for gastrointestinal symptoms in these conditions.
OBJECTIVE: This study explores the association between CeD, Systemic Lupus Erythematosus (SLE), primary Sjogren syndrome (pSS), and Systemic Sclerosis (SSc).
METHODS: A systematic review and meta-analysis were conducted following PRISMA guidelines. Searches across multiple databases yielded 2728 articles, with 15 studies selected. Data extraction included study characteristics, prevalence of CeD and CeD antibodies in SLE, pSS, and SSc. Quality assessment utilized the Newcastle-Ottawa Scale.
RESULTS: The meta-analysis revealed a pooled prevalence of biopsy-proven CeD in SLE, pSS, and SSc of approximately 3%. Seroprevalence of any CeD antibody in SLE, pSS, and SSc ranged from 3% to 10%. Notably, pSS exhibited the highest prevalence at 5.59%. High heterogeneity was observed in seroprevalence across autoimmune conditions. Quality assessment indicated robust methodological quality in the selected studies.
CONCLUSIONS: This study highlights a significantly higher prevalence of CeD, especially pSS, compared to the general population. The findings underscore the importance of recognizing elevated CeD antibodies in patients with SLE, pSS and SSc emphasizing the need for early detection and comprehensive care for gastrointestinal symptoms in these conditions.
摘要：
背景：乳糜泻（CeD）是一种影响小肠的免疫介导的疾病，与遗传因素和全球患病率增加有关。
目的：本研究探讨了CeD，系统性红斑狼疮(SLE),原发性干燥综合征（pSS），和系统性硬化症（SSc）。
方法：按照PRISMA指南进行系统评价和荟萃分析。跨多个数据库的搜索产生了2728篇文章，选择了15项研究。数据提取包括研究特征，SLE中CeD和CeD抗体的患病率，PSS,SSC。质量评估采用纽卡斯尔-渥太华量表。
结果：荟萃分析显示，SLE中活检证实的CeD的合并患病率，PSS,SSc约为3%。SLE中任何CeD抗体的血清阳性率，PSS,SSc从3%到10%不等。值得注意的是,pSS的患病率最高，为5.59%。在自身免疫条件下的血清阳性率中观察到高度异质性。质量评估表明所选研究的方法学质量稳健。
结论：这项研究强调了CeD的患病率明显更高，尤其是PSS,与一般人口相比。这些发现强调了在SLE患者中识别CeD抗体升高的重要性。pSS和SSc强调在这些情况下需要早期发现和全面护理胃肠道症状。
目的：本研究探讨了CeD，系统性红斑狼疮(SLE),原发性干燥综合征（pSS），和系统性硬化症（SSc）。
方法：按照PRISMA指南进行系统评价和荟萃分析。跨多个数据库的搜索产生了2728篇文章，选择了15项研究。数据提取包括研究特征，SLE中CeD和CeD抗体的患病率，PSS,SSC。质量评估采用纽卡斯尔-渥太华量表。
结果：荟萃分析显示，SLE中活检证实的CeD的合并患病率，PSS,SSc约为3%。SLE中任何CeD抗体的血清阳性率，PSS,SSc从3%到10%不等。值得注意的是,pSS的患病率最高，为5.59%。在自身免疫条件下的血清阳性率中观察到高度异质性。质量评估表明所选研究的方法学质量稳健。
结论：这项研究强调了CeD的患病率明显更高，尤其是PSS,与一般人口相比。这些发现强调了在SLE患者中识别CeD抗体升高的重要性。pSS和SSc强调在这些情况下需要早期发现和全面护理胃肠道症状。
